Rivaroxaban
- 1 lab in 1 country
- Human trial1
- Humans1
Outcomes
2Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Rivaroxaban improves cognitive function in humans (mean difference 2.56, 95% CI 1.11-4.01).
Human trialafter successful left atrial appendage occlusion10 mg daily365 daysn = 164
European heart journal31 Aug 2026
Silent cerebral embolic lesions
downin humans1
1 study
Silent cerebral embolic lesions
downin humans1
Rivaroxaban decreases silent cerebral embolic lesions in humans (12.2% vs. 31.7%).
Human trialafter successful left atrial appendage occlusion10 mg daily365 daysn = 164
European heart journal31 Aug 2026
Latest
2 in 12 monthsEuropean Heart Journal
Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolism after left atrial appendage occlusion: the HALO-SCE trial
Randomised trial in 164 peopleInterventions